ストックスクリーナーアプリを入手
3.89
4.85%
0.18
アフターアワーズ：
3.91
0.02
+0.51%
前日終値:
$3.71
開ける：
$3.71
24時間の取引高:
1.06M
Relative Volume:
1.67
時価総額：
$392.31M
収益：
-
当期純損益:
$-26.25M
株価収益率:
-9.4901
EPS:
-0.4099
ネットキャッシュフロー:
$-20.05M
1週間 パフォーマンス:
-0.51%
1か月 パフォーマンス:
+10.51%
6か月 パフォーマンス:
+38.19%
1年 パフォーマンス:
-16.16%
1日の値動き範囲:
$3.68
$3.92
1週間の範囲:
$3.5801
$4.09
52週間の値動き範囲:
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
名前
Galectin Therapeutics Inc
セクター
電話
678-620-3186
住所
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
3.89 | 394.32M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 再開されました | H.C. Wainwright | Buy |
| 2020-08-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-13 | 開始されました | B. Riley FBR | Buy |
| 2017-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-10-19 | 開始されました | ROTH Capital | Buy |
| 2017-03-30 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | ダウングレード | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | ダウングレード | ROTH Capital | Buy → Sell |
| 2016-03-28 | 再開されました | H.C. Wainwright | Buy |
| 2015-09-21 | 開始されました | H.C. Wainwright | Buy |
| 2014-08-01 | ダウングレード | Aegis Capital | Buy → Hold |
| 2014-07-30 | 繰り返されました | MLV & Co | Buy |
| 2014-07-29 | 繰り返されました | MLV & Co | Buy |
| 2014-04-02 | 繰り返されました | MLV & Co | Buy |
| 2014-02-10 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-09 | 繰り返されました | Aegis Capital | Buy |
| 2013-12-03 | 開始されました | MLV & Co | Buy |
| 2013-08-19 | 繰り返されました | Aegis Capital | Buy |
すべてを表示
Galectin Therapeutics Inc (GALT) 最新ニュース
Why Is Galectin Therapeutics (NASDAQ:GALT) Breaking Out Now? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
A drug company will present in New York Sept. 14. Galectin will meet investors there. - Stock Titan
Galectin Therapeutics Stock Price Forecast. Should You Buy GALT? - StockInvest.us
Galectin Therapeutics (NASDAQ:GALT): Can Momentum Outrun Weak Results? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Galectin Therapeutics Inc. (GALT) Peer Comparison – Compare with Others - Value Research
Galectin Therapeutics Inc. (GALT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Galectin Therapeutics (NASDAQ:GALT): Is Momentum Turning Stronger? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeuti - The National Law Review
Galectin (GALT) Q1 2026 Earnings: The EPS Result Is Below Expectation for the Current Session; Share Move - vinanet.vn
Galectin (GALT) Today: Posts a 5.43% Gain to $3.88 in the Current Update; Technical Setup: the Price Remains Bounded by the Supplied Support and Resistance on the DayTriple MA Cross - vinanet.vn
Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available RecordUpward Estimate Revision - vinanet.vn
Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn
HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusSuperTrend Flip - vinanet.vn
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat
Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade
Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart
Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus
Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView
Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com
Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative
Galectin Therapeutics、2026年6月30日決算の結果を発表し、事業状況を更新 - Moomoo
GALT Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat
Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewir - The National Law Review
Galectin Therapeutics (GALT) Jumps 7% to $3.45: Biotech Breakout Gains MomentumSentiment Shift - vinanet.vn
Galectin Therapeutics (GALT) Advances 2.48% to $3.3, Holds Above Key Support LevelLiquidity Order Flow - dars.gov.et
Galectin Therapeutics (GALT) Holds Steady at $3.10 as Shares Trade Within Tight RangeDebt Free Companies - dars.gov.et
Galectin Therapeutics (GALT) Projected to Announce Quarterly Earnings on Thursday - MarketBeat
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion - The Globe and Mail
Galectin chairman converts $105.8 million debt to equity By Investing.com - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Galectin chairman converts $105.8 million debt to equity - Investing.com
Richard Uihlein converts GALT debt into 34,376,167 new shares - Stock Titan
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein - Quiver Quantitative
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet - 富途牛牛
Galectin Therapeutics (GALT) director converts credit notes into stock - Stock Titan
Galectin Therapeutics Director Richard E. Uihlein Converts Convertible Notes into 34.4 Million Shares - Kalkine Media
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Galectin Therapeutics (GALT) Slides 8% as Small-Cap Biotech Selling Pressure IntensifiesLong Short Pair - vinanet.vn
Galectin Therapeutics (GALT) Drops 8% as Shares Approach Key Support at $2.82Spring Pattern - vinanet.vn
Galectin Therapeutics Inc. Revenue Breakdown – NASDAQ:GALT - TradingView
Galectin Therapeutics Inc (GALT) 財務データ
収益
当期純利益
現金流量
EPS
Galectin Therapeutics Inc (GALT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
Jul 14 '26 |
Option Exercise |
3.04 |
16,250 |
49,400 |
16,250 |
| Jamil Khurram | Chief Medical Officer |
Jul 14 '26 |
Sale |
5.13 |
16,250 |
83,284 |
0 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Option Exercise |
1.23 |
22,268 |
27,390 |
28,768 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Option Exercise |
1.23 |
7,732 |
9,510 |
14,232 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Sale |
5.04 |
22,268 |
112,231 |
6,500 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Sale |
5.00 |
7,732 |
38,660 |
6,500 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Option Exercise |
2.50 |
47,467 |
118,668 |
47,467 |
| Jamil Khurram | Chief Medical Officer |
Jun 26 '26 |
Option Exercise |
2.37 |
4,570 |
10,814 |
2,533 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Sale |
5.04 |
47,467 |
239,234 |
0 |
| Jamil Khurram | Chief Medical Officer |
Jun 26 '26 |
Sale |
5.00 |
4,570 |
22,850 |
0 |
0.88%
大文字化:
|
ボリューム (24 時間):